Kirkland's (NASDAQ: KIRK ) reported its second quarter results. The company lost $0.06 per share, worse than the $0.03 loss analysts were expecting. Revenue of $103.50 million also fell short of analyst expectations of $104.94 million. Stage Stores (NYSE: SSI ) reported its second quarter results.
Retail ETF In Play As Handfuls Of Retailers Report Earnings - Yahoo Finance
Ukraine has denounced the move as an invasion. The U.S. and other Ukraine allies have threatened additional sanctions against Russia, which has sided with pro-Russian rebels and annexed Crimea from Ukraine. Copyright 2014 MarketWatch, Inc.
Allergan reviewing special meeting requests as Valeant ratchets up $53B hostile takeover bid | Fox Business
That's a change fellow drugmaker Valeant Pharmaceuticals is seeking as part of its hostile takeover attempt. Allergan has repeatedly rejected Valeant's offers to buy the company, the latest for about $53 billion, saying Valeant is substantially undervaluing the company and that an independent Allergan can generate more value for shareholders. Valeant and its partner investment fund manager Pershing Square said late Friday they submitted to Allergan written requests from its shareholders of 31 percent of Allergan's stock requesting a special meeting of Allergan shareholders. Allergan says it will announce details on a possible meeting once it finishes reviewing the requests. Valeant says it believes Allergan must hold that meeting by Dec. 20.
Pharma ETF Investing 101 - ETF News And Commentary - NASDAQ.com
Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations. Most of these companies are re-evaluating their pipelines and discontinuing programs which do not have a favorable http://www.etftradingsignals.com risk-benefit profile. Emerging Markets The pharma industry has also been looking towards emerging markets for growth. However, bribery investigations on some pharma companies in China, one of the most promising emerging markets, could put a lid on near-term growth. (Read: 3 ETFs to cash in on ageing global population ) New Drugs to Drive Growth Several important products have gained approval so far this year including oral multiple sclerosis drug Tecfidera, type II diabetes drug Invokana, Liptruzet (cholesterol), Fetzima (major depressive disorder), Imbruvica (mantle cell lymphoma), Gazyva (chronic lymphocytic leukemia) and Sovaldi (HCV).
It's feast or famine for farmers who grow for Market Basket; farmers markets are thriving | Fox Business
Health care also has a double-digit allocation. Director and portfolio manager of China Asset Management Limited, David Lai had this to say about the health care sector in China: I believe the health care sector will enjoy very significant growth in the next few years' time. China has a very young population of 1.3 billion. However, it is aging very rapidly due to the one child policy implemented 30 years ago. Related Link: 3 Reasons To Follow The Big Dog In Natural Resources This unique fund offers exposure to privately owned small- and medium-sized enterprises (SMEs), many of which have had a lot to do with the rapid technological innovation and economic growth in China over the last few years. The SMEs are the work horse behind Chinas booming economy, contributing an eye popping 60 percent of China's GDP and 80 percent of its employment. Many of the stocks in the CXNT portfolio are considered new economy sectors in China, with high potential for growth.
New China ETF Tracking Growth Sectors - Yahoo Finance
But all farmers are not reaping full benefits. Methuen, Massachusetts, farmer Rich Bonanno raised 80,000 mums to sell to Market Basket for $240,000. He's now trying to sell them cheaper to cut his losses. But in Hollis, Massachusetts, Tyler Hardy of Brookdale Fruit Farm is working 95 hours a week to meet demand at competing grocery chains.